Despite pressure from the White House, researchers may not be able to say whether the vaccine works until after the election.
Phase 3 clinical trials for the much-anticipated Oxford COVID-19 vaccine are set to begin in the United States Wednesday, with participants in Madison, Wisconsin rolling up their sleeves for the injection.
The first participant to sign up is UW's chief quality officer and an emergency medicine physician, Dr. Jeff Pothof. He's scheduled to get the shot on Wednesday, but is not otherwise involved in the research. Participants must be followed for at least a month after that second shot to measure their levels of antibodies against the coronavirus. With that timeframe in mind, it would be around Thanksgiving before the company has at least preliminary data, Hartman said.
The Oxford vaccine uses a well-known virus, called an adenovirus, which causes the common cold. It's genetically altered so it doesn't make a person sick. Instead, it teaches the immune system how to generate antibodies to attack what's called the spike protein on the surface of the coronavirus. It's that spike protein that gets into human cells, wreaking havoc.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
AstraZeneca expands COVID-19 vaccine supply tie-up with Oxford BiomedicaAstraZeneca has expanded its agreement with Oxford Biomedica to make and supply the drugmaker's COVID-19 vaccine candidate, in a deal that will pay the gene and cell therapy firm $15 million upfront and an additional $35 million plus other costs by the end of 2021.
Read more »
The University of Oxford is set to begin large trials of its COVID-19 vaccine in the U.S.Despite pressure from the White House, researchers may not be able to say whether the vaccine works until after the election.
Read more »
Florida Cuts Ties With Large Coronavirus Testing Lab, Citing 75,000 Delayed ResultsQuest Diagnostics accounts for roughly 30% of Florida's total of some 4.6 million tests. The state calls the release of results from weeks or months ago an 'unacceptable dump of test results.'
Read more »
Large antibody study offers hope for virus vaccine effortsBREAKING: Study suggests immune system's coronavirus-fighting antibodies do not fade quickly, a hopeful sign for vaccine efforts. A report from tests on more than 30,000 people in Iceland show the antibodies last at least four months after diagnosis.
Read more »
Economist El-Erian says derivatives show retail traders may be drowned by a large correction in stocks | Markets InsiderMohamed El-Erian said in an op-ed in the Financial Times that the boom in retail trading may slow down as the options market is signalling a cor...
Read more »
FDA: COVID Vaccine Could Be Given Before Tests EndEmergency use authorization or approval for a COVID-19 vaccine before Phase 3 clinical trials are complete could be considered by the U.S. Food and Drug Administratio
Read more »